Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectiveness And Impact on Liver Fibrosis (MASTER Cohort)

Trial Profile

Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectiveness And Impact on Liver Fibrosis (MASTER Cohort)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Atazanavir (Primary) ; Atazanavir/ritonavir; Darunavir/ritonavir
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top